InFlectis BioScience is a private clinical stage company based in France committed to the development of novel therapeutics that improve the life of patients. InFlectis BioScience is focused on the development of its lead drug candidate IFB-088 for the treatment of Charcot-Marie-Tooth disease. A second series of small molecules is being developed to address inflammation associated diseases and cancers.

Harnessing the Integrated Stress Response by the pharmacological modulation of eIF2 dephosphorylation to restore the cellular homeostasis, is a new frontier pioneered by InFlectis BioScience since 2013, based on many years of academic R&D. The company aims at becoming a leader in drug development targeting the Integrated Stress Response signaling pathway.

InFlectis BioScience operates as a semi-virtual pharmaceutical company in cost and capital efficient manner. The InFlectis BioScience management team has a long and successful track record in pharmaceutical industry with a deep experience in drug discovery and development.

The Scientific Advisory Board comprises prominent scientists with strong experience in Integrated Stress Response signaling, animal models in neurodegenerative diseases, regulatory preclinical and clinical development of drug.